Find the right Medicare plan for 2026 — compare coverage and costs in minutes.

Compare Medicare Plans →
Medicare News MedCity News

QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll

QuantHealth raised $45 million in Series B funding to expand its AI platform, which simulates clinical trials before they run and predicts patient outcomes for pharma companies. The startup is aiming to cut the industry’s 90% trial failure rate and speed up the timelines for effective drugs to reach the market. The post QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll appeared first on MedCity News .

Read full article →
Medicare News MedCity News

Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents

Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a partnership with AstraZeneca on a protein degrader from the pharma company’s cancer drug pipeline. The post Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents appeared first on MedCity News .

Read full article →
Medicare News MedCity News

HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased

HHS is reviving a rebate program for 340B drug discounts after the previous pilot was blocked in court earlier this year. Providers say the change will burden already cash-strapped providers with new administrative and financial costs. The post HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased appeared first on MedCity News .

Read full article →
Medicare News MedCity News

Report: Telehealth Uptake Is Lagging in Rural Areas

An Elevance Health Public Policy Institute study found rural patients used telehealth less than non-rural patients across all chronic conditions and insurance types. The post Report: Telehealth Uptake Is Lagging in Rural Areas appeared first on MedCity News .

Read full article →
Medicare News MedCity News

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease. The post Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company appeared first on MedCity News .

Read full article →